Codex DNA Inc
NASDAQ:DNAY
Intrinsic Value
Codex DNA, Inc. engages in research and development of genomic tools for biomedical and industrial applications. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of DNAY.
Fundamental Analysis
Balance Sheet Decomposition
Codex DNA Inc
| Current Assets | 55.1m |
| Cash & Short-Term Investments | 43.6m |
| Receivables | 5.9m |
| Other Current Assets | 5.7m |
| Non-Current Assets | 26.3m |
| PP&E | 8.5m |
| Intangibles | 16.8m |
| Other Non-Current Assets | 981k |
| Current Liabilities | 13.5m |
| Accounts Payable | 1.3m |
| Accrued Liabilities | 7.8m |
| Other Current Liabilities | 4.4m |
| Non-Current Liabilities | 21.3m |
| Long-Term Debt | 19.7m |
| Other Non-Current Liabilities | 1.6m |
Earnings Waterfall
Codex DNA Inc
|
Revenue
|
27.4m
USD
|
|
Cost of Revenue
|
-11.8m
USD
|
|
Gross Profit
|
15.6m
USD
|
|
Operating Expenses
|
-62.1m
USD
|
|
Operating Income
|
-46.5m
USD
|
|
Other Expenses
|
-2m
USD
|
|
Net Income
|
-48.5m
USD
|
Free Cash Flow Analysis
Codex DNA Inc
DNAY Profitability Score
Profitability Due Diligence
Codex DNA Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Codex DNA Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
DNAY Solvency Score
Solvency Due Diligence
Codex DNA Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
Codex DNA Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DNAY Price Targets Summary
Codex DNA Inc
Ownership
DNAY Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
DNAY Price
Codex DNA Inc
| Average Annual Return | -3% |
| Standard Deviation of Annual Returns |
N/A
|
| Max Drawdown | -95% |
| Market Capitalization | 59.8m USD |
| Shares Outstanding | 29 521 800 |
| Percentage of Shares Shorted | 1.2% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Codex DNA, Inc. engages in research and development of genomic tools for biomedical and industrial applications. The company is headquartered in San Diego, California and currently employs 212 full-time employees. The company went IPO on 2021-06-18. The firm is focused on enabling researchers to build or write synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) that is ready to use in downstream synthetic biology enabled markets. Its synthetic biology solutions include the BioXp 3250 system, BioXp kits, BioXp portal, Benchtop reagent kits and Biofoundry services. Its BioXp system is an end-to-end automated workstation. The firm's BioXp kits contain all the necessary building blocks and reagents, including the Company's Gibson Assembly branded reagents. The BioXp portal is a user-friendly online portal that offers a guided workflow and design tools. Benchtop reagent kits contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system. Its Biofoundry services enable a customer to order and receive any of the BioXp system endpoint-ready products.
You don't have any saved screeners yet
